MedTrace Logo

Quadratus Lumborum vs Erector Spinae Supplementary Blocks With Lumbar Plexus Blocks for Hip PAO

NCT04481451 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2025-12-12

No results posted yet for this study

Summary

This study proposes to evaluate the efficacy of single shot erector spinae block (ESB) versus single shot quadratus lumborum block (QLB) when used in conjunction with continuous lumbar plexus block (LPB) for postoperative analgesia in children and adolescents undergoing unilateral hip surgical procedures. The aim of this study is to compare the efficacy of the QL vs. ESP blocks as supplements to the lumbar plexus block with respect to pain control outcomes after hip PAO surgery. Both blocks are safe and easy to perform. There is currently no comparative, prospective data concerning the use of these two blocks for hip surgery. The investigational hypothesis is that there will be no clinical difference in the amount of opioid consumed or the overall pain control offered by these two block options.

Conditions

  • Pain, Postoperative
  • Regional Anesthesia
  • Hip Dysplasia

Interventions

PROCEDURE

Erector spinae block with ropivacaine 0.2%

Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.

PROCEDURE

Quadratus lumborum block with ropivacaine 0.2%

Single-shot ultrasound-guided nerve block performed ipsilateral to surgical site.

DRUG

Ropivacaine

ropivacaine 0.2% nerve block injection

Sponsors & Collaborators

Principal Investigators

  • ROLAND BRUSSEAU, MD · Boston Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2025-12-01
Completion
2025-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04481451 on ClinicalTrials.gov